Association of Expression of ERCC1/RRM1 with Survival and Resistance to Platinum Inpatients with Ⅰ-ⅢA NSCLC
|School||Dalian Medical University|
|Keywords||ERCC1 (Excision repair cross-complementation gene 1 excision repair cross complementing gene 1 ) RRM1 (Ribonucleotide reductase subunit 1 ribonucleotide reductase MI) Non-small cell lung cancer (NSCLC) Survival (OS) Disease-free survival (DFS)|
Objective: To analyze the nucleotide excision repair system members ERCC1/RRM1 in Ⅰ - Ⅲ A non-small cell lung cancer (NSCLC) tissue levels to explore its survival in NSCLC patients with platinum-resistant and relevance, patients with NSCLC individualized treatment to provide a theoretical basis. Materials and Methods: 1. Randomly selected 280 cases in our hospital 2004-2007 NSCLC patients after surgery, and follow-up clinical data aggregated survival, screened 160 patients enrolled in the study. (2) using tissue micro array systems planting cut tissue samples were detected by immunohistochemistry in lung cancer ERCC1/RRM1 expression levels. 3 using X2 inspection, Kaplan Meier survival analysis method, the survival curve for log-rank test, and Cox proportional hazards regression model analysis of multiple survival factors, the application of Spearman correlation analysis to explore the correlation between the expression ERCC1/RRM1. Results: 1.ERCC1 RRM1 in NSCLC tissues with positive expression rates were 55% and 49%. 2 in NSCLC ERCC1 expression with age, gender, smoking index, histological type and lymph node metastasis was no significant correlation (P gt; 0.05), with the degree of tumor differentiation correlated with statistical significance (P = 0.04 ), showed lower the degree of tumor differentiation ERCC1-positive rate. NSCLC, RRM1 expression and age, gender, smoking index, histological type, degree of differentiation and lymph node metastasis was no significant correlation (P gt; 0.05). 3.160 cases of patients, ERCC1/RRM1 negative expression prolonged survival compared to positive, the difference was not statistically significant (P gt; 0.05). 4 follow-up of patients with stage Ⅰ B NSCLC survival, ERCC1 expression is longer than those with negative expression, but the difference was not statistically significant (P gt; 0.05), RRM1 positive longer than the lifetime of the negative, the difference was statistically significant (P = 0.03); follow-Ⅱ - Ⅲ A survival of NSCLC patients, ERCC1 expression was negative than positive group extension, the difference was statistically significant (P = 0.03), RRM1 negative group prolong survival compared to positive group, but the difference was not statistically significant ( P gt; 0.05). 5. Ⅰ B expression of ERCC1/RRM1 positive, no chemotherapy group survival compared with chemotherapy prolonged survival of the group, but the difference was not statistically significant (P gt; 0.05); Ⅰ B negative expression of ERCC1/RRM1 when without chemotherapy prolonged survival compared to chemotherapy group, the difference was not statistically significant (P gt; 0.05). 6 Observe Ⅱ - Ⅲ A period RRM1 expression levels are the same, GP regimen on survival, the results show: RRM1 expression was negative when, GP regimen group, the median survival compared to TP, NP and other platinum-containing chemotherapy patients prolonged survival (40 months: 36 months), the difference was not statistically significant (P = 0.21); RRM1 expression, the other with platinum-based chemotherapy group, the median survival time is longer than the GP regimen chemotherapy group, the difference was not statistically significance (P = 0.12). 7 Multivariate Cox regression analysis showed: lymph node metastasis, histological type, tumor differentiation NSCLC patients is an independent prognostic factor. Conclusion: 1.ERCC1 protein in NSCLC tissues with gender, age, smoking index, histological type and lymph node metastasis, and degree of differentiation; RRM1 protein in NSCLC tissues with gender, age, smoking index, histological type , differentiation and lymph node metastasis. 2. Ⅰ B adjuvant chemotherapy in patients more harm than good. 3.ERCC1 expression and Ⅱ - Ⅲ A NSCLC, platinum-containing chemotherapy efficacy related to expression, the chemotherapy group compared with no chemotherapy group poor efficacy. 4.RRMl expression when, GP program than TP, NP and other platinum-containing chemotherapy regimens suboptimal; negative expression when, GP program than TP, NP and other platinum-based chemotherapy is effective. 5.ERCC1 with RRM1 has obvious relevance.